You are here
FDA Approves Ertaczo Cream
In October 2003, Mylan announced the sale of the U.S. and Canadian rights for sertaconazole to the OrthoNeutrogena Division of Ortho-McNeil Pharmaceutical Inc. (OrthoNeutrogena), terminating the licensing rights it held to sertaconazole from Ferrer Internacional S.A. Mylan received $2 million upon signing the agreement with OrthoNeutrogena and will receive the additional $12 million as a result of the FDA’s final approval of its NDA.
The product will be marketed by OrthoNeutrogena.
Source: Mylan Laboratories Inc.